Progress and problems in the exploration of therapeutic targets (DOI:10.1016/j.drudis.2006.03.012);Progress and problems in the exploration of therapeutic targets

Drug Discovery Today

Volumn 11, Issue 9-10, 2006, Pages 412-420

  Zheng, Chanjuan ^a   Han, Lianyi ^a   Yap, Chun W ^a   Xie, Bin ^a   Chen, Yuzong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ABARELIX; ADEFOVIR DIPIVOXIL; ALMOTRIPTAN; AMLODIPINE PLUS ATORVASTATIN; AMPRENAVIR PHOSPHATE; APOMORPHINE; ATAZANAVIR; ATOVAQUONE PLUS PROGUANIL; BETAXOLOL; BOSENTAN; CASPOFUNGIN; CELECOXIB; CETUXIMAB; CLOFARABINE; EFAVIRENZ; ELETRIPTAN; ENTECAVIR; EPROSARTAN; ERLOTINIB; FROVATRIPTAN; FULVESTRANT; GEFITINIB; IMATINIB; LETROZOLE; LEUPRORELIN; LEVOFLOXACIN; LOPINAVIR PLUS RITONAVIR; MITOXANTRONE; MOXIFLOXACIN; OLMESARTAN; PEGAPTANIB; PEMETREXED; RAMELTEON; SILDENAFIL; SOTALOL; TENOFOVIR DISOPROXIL; TIPRANAVIR; TOSITUMOMAB I 131; TRASTUZUMAB; TRAVOPROST; UNINDEXED DRUG; VALSARTAN; ZOLMITRIPTAN;

ARTHRITIS; BACTERIAL INFECTION; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TARGETING; ERECTILE DYSFUNCTION; FEASIBILITY STUDY; GENITAL TRACT CANCER; HEART DISEASE; HEPATITIS B; HUMAN; ISCHEMIA; LEUKEMIA; LUNG CANCER; LYMPHOMA; MESOTHELIOMA; MOLECULAR DYNAMICS; MYCOSIS; PARASITOSIS; PATENT; PHYSICAL CHEMISTRY; PREDICTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; VIRUS INFECTION;

EID: 33646532662     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.06.005     Document Type: Erratum

References (64)

1. Ohlstein E.H., et al. Drug discovery in the next millennium. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 177-191
2. Drews J. Strategic choices facing the pharmaceutical industry: a case for innovation. Drug Discov. Today 2 (1997) 72-78
3. Debouck C., and Metcalf B. The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 193-207
4. Sali A. 100 000 protein structures for the biologist. Nat. Struct. Biol. 5 (1998) 1029-1032
5. Dove A. Proteomics: translating genomics into products?. Nat. Biotechnol. 17 (1999) 233-236
6. Macdonald I.A. Obesity: are we any closer to identifying causes and effective treatments?. Trends Pharmacol. Sci. 21 (2000) 334-336
7. Walke D.W., et al. In vivo drug target discovery: identifying the best targets from the genome. Curr. Opin. Biotechnol. 12 (2001) 626-631
8. Ilag L.L., et al. Emerging high-throughput drug target validation technologies. Drug Discov. Today 7 Suppl. 18 (2002) 136-142
9. Nicholls H. Improving drug response with pharmacogenomics. Drug Discov. Today 8 (2003) 281-282
10. Chiesi M., et al. Pharmacotherapy of obesity: targets and perspectives. Trends Pharmacol. Sci. 22 (2001) 247-254
11. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 6 (2001) 1005-1024
12. Greenfeder S., and Anthes J.C. New asthma targets: recent clinical and preclinical advances. Curr. Opin. Chem. Biol. 6 (2002) 526-533
13. Vane J.R., et al. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
14. Torphy T.J., and Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol. Sci. 21 (2000) 157-159
15. Kennedy B.P., and Ramachandran C. Protein tyrosine phosphatase-1B in diabetes. Biochem. Pharmacol. 60 (2000) 877-883
16. Chen X., et al. TTD: Therapeutic Target Database. Nucleic Acids Res. 30 (2002) 412-415
17. van de Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2 (2003) 192-204
18. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today 2 (1997) 436-444
19. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
20. Zambrowicz B.P., and Sands A.T. Knockouts model the 100 best-selling drugs-will they model the next 100?. Nat. Rev. Drug Discov. 2 (2003) 38-51
21. Lin P.C., et al. Female genital anomalies affecting reproduction. Fertil. Steril. 78 (2002) 899-915
22. Kobayashi H., and Stringer M.D. Biliary atresia. Semin. Neonatol. 8 (2003) 383-391
23. Buolamwini J.K. Novel anticancer drug discovery. Curr. Opin. Chem. Biol. 3 (1999) 500-509
24. Elsayed Y.A., and Sausville E.A. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 6 (2001) 517-537
25. Persidis A. Cardiovascular disease drug discovery. Nat. Biotechnol. 17 (1999) 930-931
26. Bicknell K.A., et al. Targeting the cell cycle machinery for the treatment of cardiovascular disease. J. Pharm. Pharmacol. 55 (2003) 571-591
27. Lewis A.J., and Manning A.M. New targets for anti-inflammatory drugs. Curr. Opin. Chem. Biol. 3 (1999) 489-494
28. Wagman A.S., and Nuss J.M. Current therapies and emerging targets for the treatment of diabetes. Curr. Pharm. Des. 7 (2001) 417-450
29. Blake S.M., and Swift B.A. What next for rheumatoid arthritis therapy?. Curr. Opin. Pharmacol. 4 (2004) 276-280
30. Bray G.A., and Tartaglia L.A. Medicinal strategies in the treatment of obesity. Nature 404 (2000) 672-677
31. Clapham J.C., et al. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol. Ther. 89 (2001) 81-121
32. Windisch M., et al. Current drugs and future hopes in the treatment of Alzheimer's disease. J. Neural Transm. Suppl. 62 (2002) 149-164
33. Irizarry M.C., and Hyman B.T. Alzheimer disease therapeutics. J. Neuropathol. Exp. Neurol. 60 (2001) 923-928
34. Drews J. Stategic trends in the drug industry. Drug Discov. Today 8 (2003) 411-420
35. Smith, C. (2003) Drug target validation: hitting the target. Nature 422, 341, 343, 345 passim.
36. Kehne J., and De Lombaert S. Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 1 (2002) 467-493
37. Young R.N., et al. L-649,923, sodium (beta S*, gamma R*-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-gamma-hydr oxy -beta-methylbenzenebutanoate. A selective, orally active leukotriene D4 receptor antagonist. Adv. Prostaglandin Thromboxane Leukot. Res. 16 (1986) 37-45
38. Dunn C.J., and Goa K.L. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. Drugs 61 (2001) 285-315
39. Altschul S.F., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25 (1997) 3389-3402
40. Bairoch A., et al. Swiss-Prot: juggling between evolution and stability. Brief. Bioinform. 5 (2004) 39-55
41. Kanehisa M., et al. The KEGG resource for deciphering the genome. Nucleic Acids Res. 32 (2004) D277-D280
42. George R.A., and Heringa J. Protein domain identification and improved sequence similarity searching using PSI-BLAST. Proteins 48 (2002) 672-681
43. Gerstein M. Measurement of the effectiveness of transitive sequence comparison through a third 'intermediate' sequence. Bioinformatics 14 (1998) 707-714
44. Koehl P., and Levitt M. Sequence variations within protein families are linearly related to structural variations. J. Mol. Biol. 323 (2002) 551-562
45. Wood T.C., and Pearson W.R. Evolution of protein sequences and structures. J. Mol. Biol. 291 (1999) 977-995
46. Sternberg J.M. Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol. 26 (2004) 469-476
47. Fikkert V., et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18 (2004) 2019-2028
48. Lee N., et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J. Clin. Virol. 31 (2004) 304-309
49. Beard C.W., and Mason P.W. Genetic determinants of altered virulence of Taiwanese foot-and-mouth disease virus. J. Virol. 74 (2000) 987-991
50. Song H., et al. Molecular determinants of infectious pancreatic necrosis virus virulence and cell culture adaptation. J. Virol. 79 (2005) 10289-10299
51. Lacombe C., and Mayeux P. Biology of erythropoietin. Haematologica 83 (1998) 724-732
52. Siddiqui N.I., et al. Evaluation of hormone replacement therapy. Mymensingh Med. J. 14 (2005) 212-218
53. Zick Y. Molecular basis of insulin action. Novartis Found. Symp. 262 (2004) 36-50
54. Petersenn S. Structure and regulation of the growth hormone secretagogue receptor. Minerva Endocrinol. 27 (2002) 243-256
55. Huber W. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. J. Mol. Recognit. 18 (2005) 273-281
56. Bursi R., and Groen M.B. Application of (quantitative) structure-activity relationships to progestagens: from serendipity to structure-based design. Eur. J. Med. Chem. 35 (2000) 787-796
57. Gooren L.J., and Nguyen N.T. One and the same androgen for all? Towards designer androgens. Asian J. Androl. 1 (1999) 21-28
58. Sanseau P. Impact of human genome sequencing for in silico target discovery. Drug Discov. Today 6 (2001) 316-323
59. Desany B., and Zhang Z. Bioinformatics and cancer target discovery. Drug Discov. Today 9 (2004) 795-802
60. Han L.Y., et al. Predicting functional family of novel enzymes irrespective of sequence similarity: a statistical learning approach. Nucleic Acids Res. 32 (2004) 6437-6444
61. Burges C. A tutorial on Support Vector Machine for pattern recognition. Data Min. Knowl. Disc. 2 (1998) 121-167
62. Wise A., et al. Target validation of G-protein coupled receptors. Drug Discov. Today 7 (2002) 235-246
63. Duckworth D.M., and Sanseau P. In silico identification of novel therapeutic targets. Drug Discov. Today 7 Suppl. 11 (2002) 64-69
64. Chen Y.Z., and Zhi D.G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 43 (2001) 217-226